AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China

$1.2bn Validation Of Chinese Capabilities

 
• By Brian Yang
arrow pointing to the year 2024 on a raised metal dial
AstraZeneca acquires Gracell Bio in validation of China cell therapy innovation • Source: Shutterstock

More from China

More from Focus On Asia